Korro Bio, Inc. (NASDAQ:KRRO) Given Consensus Rating of “Buy” by Analysts

Shares of Korro Bio, Inc. (NASDAQ:KRRO) have been assigned a consensus rating of “Buy” from the seven research firms that are presently covering the stock, Marketbeat.com reports. Six investment analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $142.57.

KRRO has been the topic of several research reports. HC Wainwright reissued a “buy” rating and set a $115.00 price target on shares of Korro Bio in a research report on Friday, November 22nd. Royal Bank of Canada cut their target price on shares of Korro Bio from $105.00 to $95.00 and set an “outperform” rating on the stock in a report on Wednesday. Finally, Oppenheimer initiated coverage on shares of Korro Bio in a research report on Friday, January 10th. They issued an “outperform” rating and a $155.00 price objective on the stock.

Korro Bio Price Performance

KRRO opened at $23.72 on Thursday. Korro Bio has a 1-year low of $18.50 and a 1-year high of $98.00. The company has a 50-day moving average of $30.42 and a 200-day moving average of $41.70.

Korro Bio (NASDAQ:KRRO) last announced its quarterly earnings data on Tuesday, March 18th. The company reported ($2.26) earnings per share for the quarter, beating the consensus estimate of ($2.33) by $0.07. The firm had revenue of $2.27 million during the quarter. On average, sell-side analysts anticipate that Korro Bio will post -9.52 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Korro Bio

Institutional investors have recently bought and sold shares of the stock. KLP Kapitalforvaltning AS bought a new stake in shares of Korro Bio during the 4th quarter worth about $53,000. Quest Partners LLC boosted its holdings in shares of Korro Bio by 172.1% in the third quarter. Quest Partners LLC now owns 1,777 shares of the company’s stock valued at $59,000 after acquiring an additional 1,124 shares in the last quarter. AlphaQuest LLC increased its stake in shares of Korro Bio by 23.2% during the fourth quarter. AlphaQuest LLC now owns 2,189 shares of the company’s stock valued at $83,000 after acquiring an additional 412 shares during the period. Brown Brothers Harriman & Co. raised its holdings in Korro Bio by 251.0% during the third quarter. Brown Brothers Harriman & Co. now owns 2,854 shares of the company’s stock worth $95,000 after purchasing an additional 2,041 shares in the last quarter. Finally, Vestcor Inc bought a new stake in Korro Bio during the third quarter worth approximately $100,000. Institutional investors and hedge funds own 13.18% of the company’s stock.

About Korro Bio

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).